Scarica l'app Stockscreener
19.58
1.36%
-0.27
Dopo l'orario di chiusura:
19.40
-0.18
-0.92%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SDGR Giù?
Forum
Previsione
Precedente Chiudi:
$19.85
Aprire:
$19.57
Volume 24 ore:
996.08K
Relative Volume:
0.79
Capitalizzazione di mercato:
$1.46B
Reddito:
$254.91M
Utile/perdita netta:
$-103.48M
Rapporto P/E:
-13.95
EPS:
-1.4036
Flusso di cassa netto:
$-148.35M
1 W Prestazione:
+6.07%
1M Prestazione:
+30.53%
6M Prestazione:
+69.82%
1 anno Prestazione:
+1.14%
Intervallo 1D:
$19.31
$20.13
Intervallo di 1 settimana:
$17.16
$20.13
Portata 52W:
$10.95
$23.02
Schrodinger Inc Stock (SDGR) Company Profile
Nome
Schrodinger Inc
Settore
Industria
Telefono
503-299-1150
Indirizzo
1540 BROADWAY, NEW YORK, NY
Compare SDGR vs VEEV, TEM, BTSG, HQY, TXG
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
19.58 | 1.48B | 254.91M | -103.48M | -148.35M | -1.4036 |
VEEV
Veeva Systems Inc
|
250.53 | 40.77B | 3.32B | 941.65M | 1.64B | 5.6161 |
TEM
Tempus Ai Inc
|
66.65 | 11.05B | 1.36B | -302.91M | -219.93M | -1.7182 |
BTSG
Brightspring Health Services Inc
|
59.53 | 11.74B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
104.27 | 8.69B | 1.34B | 230.70M | 440.96M | 2.6695 |
TXG
10 X Genomics Inc
|
63.87 | 8.10B | 638.78M | -22.66M | 122.18M | -0.1744 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-09-30 | Iniziato | Goldman | Neutral |
| 2025-08-15 | Downgrade | Citigroup | Buy → Neutral |
| 2025-08-14 | Iniziato | Barclays | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-07-02 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | Ripresa | Piper Sandler | Overweight |
| 2022-12-19 | Iniziato | Goldman | Neutral |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-13 | Iniziato | Berenberg | Buy |
| 2021-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | Iniziato | Craig Hallum | Buy |
| 2020-11-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-10-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-02 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-02 | Iniziato | Jefferies | Hold |
| 2020-03-02 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Schrodinger Inc Borsa (SDGR) Ultime notizie
Schrödinger (SDGR) Q2 2026 Earnings Call Transcript - AOL.com
Schrodinger (NASDAQ:SDGR) Trading 10.4% HigherWhat's Next? - MarketBeat
BMO Capital Maintains Schrodinger(SDGR.US) With Buy Rating, Maintains Target Price $24 - Moomoo
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - Zacks Investment Research
Schrodinger Inc. (SDGR) Slides 4.7% to $17.59 as Bearish Momentum BuildsCounter Trend Trade - Vinanet
SDGR Looks 29.7% Undervalued on GF Value™ - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Schrodinger (SDGR) Slides 4.7% to $17.59 as Selling Pressure MountsSynthetic Short - Vinanet
Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Sc - GuruFocus
UBS initiates Schrodinger stock coverage with neutral rating By Investing.com - Investing.com South Africa
SDGR Assumed by UBS -- Price Target Raised to $19.00 - GuruFocus
UBS Maintains Schrodinger(SDGR.US) With Hold Rating, Maintains Target Price $19 - Moomoo
Schrodinger Coverage Assumed by UBS at Neutral - Moomoo
UBS Adjusts Schrodinger PT to $19 From $13, Maintains Neutral Rating - marketscreener.com
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Two New Schrödinger Hires Get Stock Awards Vesting Over Four Years - Stock Titan
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
UBS initiates Schrodinger stock coverage with neutral rating - Investing.com Nigeria
UBS Initiates Schrodinger(SDGR.US) With Hold Rating, Announces Target Price $19 - Moomoo
Schrodinger, Inc. Stock 12‑Month Price Target Raised to $21.83, Implies 18% Upside - TradingView
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR) - The Globe and Mail
Schrodinger, Inc. (SDGR) Stock Forecasts - Yahoo! Finance Canada
Quantinno Capital Management LP Buys Shares of 174,095 Schrodinger, Inc. $SDGR - MarketBeat
Schrödinger (SDGR) Is Up 19.2% After AI Pact With BMS And Q2 ProfitabilityHas The Bull Case Changed? - simplywall.st
Schrödinger Unveils Bunsen, an AI Co-Scientist for Enhanced Molecular Discovery - SynBioBeta
SDGR Q2 2026 Earnings: EPS of $0.08 Beats Estimates with a 116.27% SurpriseReturn On Capital - Vinanet
Dimensional Fund Advisors LP Cuts Holdings in Schrodinger, Inc. $SDGR - MarketBeat
Results: Schrödinger, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - webull.com
The Bull Case For Bristol Myers Squibb (BMY) Could Change Following Expanded Schrödinger Bunsen AI Partnership - Sahm
Schrödinger, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Moomoo
Schrodinger (NASDAQ:SDGR) Raised to "Hold" at Wall Street Zen - MarketBeat
Schrodinger Inc (SDGR) Stock Analysis & Forecast - TradingKey
Schrodinger Inc (SDGR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Schrodinger Inc. (SDGR) Dips 0.95% to $17.64 as Shares Sit Between Support and ResistanceHigh Low Breadth - dars.gov.et
Schrödinger expands partnership with Bristol Myers Squibb - Investing.com Nigeria
BofA Securities Maintains Schrodinger(SDGR.US) With Buy Rating - Moomoo
TD Cowen Maintains Schrodinger(SDGR.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Schrodinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery - marketscreener.com
Schrödinger Q2 2026 slides: AI launch, Ajax milestone drive beat By Investing.com - Investing.com South Africa
Schrödinger, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SDGR) 2026-08-06 - Seeking Alpha
SDGR Looks 36.9% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Schrodinger Q2 Earnings Call Highlights - MarketBeat
SDGR SWOT Analysis: Key Financial Insights from 10-Q Filing - GuruFocus
Schrodinger Inc (SDGR) (Q2 2026) Earnings Call Highlights: ACV S - GuruFocus
Schrödinger (SDGR) Is Up 8.5% After AI Co‑Scientist Deal With BMS And Q2 Profitability Shift – Has The Bull Case Changed? - Yahoo Finance
Schrodinger Inc (SDGR) (Q2 2026) Earnings Call Highlights: ACV Surges 27% on Bunsen Launch and ... - Yahoo! Finance Canada
Earnings call transcript: Schrödinger beats Q2 2026 forecasts as shares rise - Investing.com South Africa
Schrodinger (NASDAQ:SDGR) Announces Quarterly Earnings Results - marketbeat.com
Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Schrödinger : Schrödinger 2Q26 Supplemental Slides - marketscreener.com
Is Schrodinger Inc (SDGR) Undervalued After Q2 Earnings Reveal $58.9 Million Revenue? GF Score: 73/100 - GuruFocus
Schrodinger Inc Azioni (SDGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.35%
2.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):